AD | According to the National Institute of Mental Health (nimh.nih.gov, 2023), roughly 30% of people with major depressive disorder do not respond adequately to standard antidepressant therapy, a condition clinically referred to as treatment-resistant depression (TRD).
Featured Image: Photo by Thirdman
That’s a significant number of people stuck in a frustrating cycle: trying medication after medication, waiting weeks for results, and still feeling the same. If that sounds familiar, knowing what options actually exist, and why some work when others don’t, can make a real difference.
What Is Treatment-Resistant Depression, Exactly?
What is treatment-resistant depression is a question that comes up more often than most people expect. Clinically, TRD is defined as depression that has not responded to at least two different antidepressant treatments given at adequate doses and duration.
It’s worth noting that “not responding” doesn’t always mean “getting no better at all.” Some people see partial improvement but never reach remission. Others cycle through periods of feeling okay, only to relapse. Both scenarios fall under the TRD umbrella.
Key characteristics of TRD include:
- Tried two or more antidepressants without full remission
- Symptoms persist despite therapy (CBT, talk therapy, etc.)
- Depression significantly impacts daily functioning
- Relapses occur frequently even after short-term improvement
What Causes Treatment-Resistant Depression?
What causes treatment-resistant depression isn’t always a single, clear answer. It tends to be a combination of biological, psychological, and situational factors.
Biologically, some people metabolize antidepressants differently due to genetic variations in enzymes like CYP2D6 and CYP2C19. This means a standard dose of a common SSRI might be processed too quickly to have any real effect, or too slowly, causing side effects that lead people to stop taking it.
Other contributing factors include:
- Undiagnosed conditions like bipolar disorder, ADHD, or thyroid dysfunction
- Chronic stress or trauma that keeps the nervous system in a hyperactivated state
- Inflammatory markers that interfere with neurotransmitter function
- Medication non-adherence due to side effects
Understanding the root cause matters because it directly shapes which treatment is likely to work.
How Do Doctors Approach Treatment for TRD?
When standard antidepressants stop working, clinicians typically follow a stepped-care model. Here’s how that usually looks in practice:
- Reassess the diagnosis — rule out bipolar disorder, thyroid issues, or other conditions masking as depression
- Optimize current medication — adjust dose or duration before switching
- Switch or augment — try a different antidepressant class, or add a second medication (lithium, atypical antipsychotics, thyroid hormone)
- Add psychotherapy — particularly CBT or Acceptance and Commitment Therapy (ACT)
- Consider neuromodulation — TMS, ECT, or ketamine-based treatments
- Evaluate lifestyle factors — sleep, exercise, substance use, social support
This stepwise approach helps avoid jumping to aggressive interventions when simpler adjustments might work. That said, many people reach step five faster than expected.
What Medication for Treatment-Resistant Depression Is Actually Used?
Medication for treatment-resistant depression has expanded significantly over the past decade. It’s no longer just “try another SSRI.”
| Medication Type | Examples | How It Helps |
| Augmentation agents | Lithium, aripiprazole, quetiapine | Boosts effect of existing antidepressant |
| MAOI antidepressants | Phenelzine, tranylcypromine | Different mechanism, useful after SSRI failure |
| Ketamine / Esketamine | IV ketamine, Spravato (nasal) | Rapid effect on glutamate system |
| Tricyclic antidepressants | Nortriptyline, amitriptyline | Older class, effective but more side effects |
| Thyroid augmentation | T3 (liothyronine) | Can enhance antidepressant response |
Esketamine (Spravato) received FDA approval in 2019 specifically for TRD and is notable for producing results within hours rather than weeks. It’s administered in a clinical setting due to dissociative side effects and monitoring requirements.
When Is TMS a Better Option Than More Medication?
Transcranial Magnetic Stimulation (TMS) has become one of the most clinically supported non-drug options available for people who haven’t responded to medication. It uses focused magnetic pulses to stimulate underactive regions of the brain linked to mood regulation, specifically the left dorsolateral prefrontal cortex.
For patients looking into a concrete, evidence-based approach, TMS therapy in Brooklyn offers a practical path forward for treatment-resistant depression, especially when medication side effects or interactions have become a barrier.
Clinical data supports this. A 2020 multisite study published in the Journal of Psychiatric Research found that 58% of TRD patients who underwent TMS achieved a clinical response, with 37% reaching full remission.
TMS tends to be particularly well-suited for people who:
- Have had side effects from multiple antidepressants
- Prefer a medication-free approach
- Cannot tolerate ECT or are not good candidates for it
- Have a specific diagnosis of MDD (as opposed to bipolar depression)
It’s also outpatient, non-sedating, and takes about 20 minutes per session, which makes it far easier to fit into a regular schedule compared to inpatient options.
How Does ECT Compare to Newer Treatments?
Electroconvulsive therapy (ECT) has carried a stigma for decades, but it remains one of the most effective treatments available for severe TRD, with response rates ranging from 60–80% in clinical literature.
The tradeoff is real: ECT requires anesthesia, causes short-term memory disruption in some patients, and is typically reserved for the most severe cases, including those with psychotic features or acute suicidal risk.
Compared to newer options:
- ECT — highest efficacy, most invasive, memory side effects possible
- TMS — good efficacy, non-invasive, no cognitive side effects, outpatient
- Ketamine/Esketamine — fastest onset (hours), requires clinical supervision, effects may not last without maintenance doses
- Psychedelic-assisted therapy (psilocybin, currently in trials) — promising early data, not yet FDA-approved for TRD
FAQ
Q: How is TRD different from regular depression that just takes longer to treat?
A: TRD specifically requires that at least two adequate antidepressant trials have failed, not just that symptoms are slow to improve. Duration alone doesn’t define it; it’s about treatment response.
Q: Can therapy alone treat treatment-resistant depression without medication or procedures?
A: In mild-to-moderate TRD, intensive psychotherapy (especially CBT or ISTDP) can produce meaningful improvement, but for moderate-to-severe cases, it’s rarely sufficient on its own and is usually recommended alongside other interventions.
Q: Is TRD a permanent condition?
A: No. Many people with TRD eventually find a combination that works, whether that’s augmented medication, TMS, ketamine, or a combination approach. It’s treatment-resistant, not treatment-proof.
Q: Does ketamine work for everyone with TRD?
A: No. Response rates vary, and while ketamine can produce rapid mood improvement, effects often need to be maintained with repeated sessions. It’s particularly useful in acute situations or when fast relief is critical.
Leave a Reply